Comparative assessment of therapeutic modalities and the deliberate design of preclinical platforms

This presentation will explore ongoing research efforts aimed at broadening the therapeutic landscape by including innovative treatment modalities such as mRNA delivery systems, vaccination strategies or cell therapies. We will elaborate on the pros and cons of the different advanced modalities and will focus on the design of the appropriate preclinical discovery platforms needed along the drug development pathway. The choice of modality is influenced by many different factors and impacts the journey of the drug development with respect to platforms, cell sources and read-outs. We will elaborate on scientific, regulatory, technical, and logistical considerations related to the respective modality using HER2 as one of the cornerstones of cancer therapeutics.